AVNS vs PCRX
AVNS: Avanos Medical delivers non-opioid pain management and specialized nutrition feeding devices to hospitals and home care providers, reducing opioid dependency and supporting nutritional therapy across patient recovery pathways. PCRX: Pacira BioSciences is a non-opioid pain management company commercializing injectable, device, and gene therapy treatments for postsurgical and osteoarthritis pain.
Side-by-side fundamentals
| Metric | AVNS | PCRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $24.98 | $25.59 | |
| Market cap as of 2026-07-23 | $1.2B | $1.0B | |
| P/E as of 2026-07-23 | n/a | 194.68 | |
| PEG as of 2026-07-23 | n/a | 17.75 | |
| Net margin as of 2026-07-23 | -10.4% | +0.7% | PCRX higher |
| Gross margin as of 2026-07-23 | +50.0% | +79.3% | PCRX higher |
| Operating margin as of 2026-07-23 | -8.8% | +0.1% | PCRX higher |
| ROE as of 2026-07-23 | -9.6% | +0.7% | PCRX higher |
| ROA as of 2026-07-23 | -7.0% | +0.4% | PCRX higher |
| Debt / equity as of 2026-07-23 | 0.13 | 0.56 | AVNS lower |
| Revenue growth (YoY) as of 2026-07-23 | +3.9% | +4.6% | PCRX higher |
| Revenue CAGR (3y) SEC XBRL | +0.8% | +2.9% | PCRX higher |
| Beta as of 2026-07-23 | 1.60 | 0.26 | |
| 1-year return as of 2026-07-22 close | +111.2% | +14.1% | AVNS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.